Heard the latest Joke? "Compassionate use, right to

New Post Public Reply Private Reply Replies (1) Message Board
Rip Van 03
546
Heard the latest Joke? "Compassionate use, right to try".

Compassionate use actual case, as related by family member:

Patient enters Hospital, admitted, placed in the ICU Covad unit, family member approaches the attending Doctor employed by Hospital ( Different Doctor every day) submits information to the Doctor on duty for requesting application for Brilacidin compassionate use, Doctor tells patient and family he will submit it to Hospital supervisor, 2 days the Hospital returns a decision, "not enough data or information available for Brilacidin compassionate use consideration" so much for right to try, huh?

(Even if the Hospital had approved the application and the application had been approved it would have had to be completed and sent to the FDA for authorization, turn around time? Anyone's guess! Lets say the application had been approved, day 3, submitted to Innovation Pharmaceuticals Inc with approval, IP turn around time 10 days) MO.

Meanwhile, back to the patient, Lung infection running rampant day 3,4, 02 down under 92 patient laboring trying to get 02, 02 continues to drop day 5 Patient goes on ventilator lungs become more congested with infection day 6, 7, day 8 patient dies.
3

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors Monitor Class Action Against Xerox Ahead of Deadline

Updated Category News Views 313

Xerox Holdings Corporation Under Legal Scrutiny Faruqi & Faruqi, LLP, a prominent national securities law firm, is reaching out to investors of Xerox Holdings Corporation (NASDAQ: XRX) to inform them about an ongoing class action lawsuit. Investors are reminded of an important deadline for those wanting to assume the role of lead plaintiff in this case. The deadline for...

Continue Reading
UBS's Caution on Dr. Reddy's Projections Signals Concerns

Updated Category News Views 155

UBS dropped a Sell rating on Dr. Reddy's Laboratories (NSE: DRRD) back in 2024, tagging the stock with a price target of INR 5,700.00. You could feel the tension shift in trading rooms as their assessment sparked fresh chatter about the firm’s US base business revenue projections that seem downright optimistic. UBS Questions Revenue Estimates: Too High or Just Right?...

Continue Reading
Evaluating Apple's Business Landscape Among Top Tech Firms

Updated Category News Views 115

Assessing Market Position and Performance In the dynamic world of technology hardware, it’s crucial for investors to analyze the competition thoroughly. This article takes a closer look at Apple (NASDAQ: AAPL) and compares its financial metrics and market position against its key competitors in the industry. With this analysis, we aim to provide insights into Apple's...

Continue Reading
Back to School: Parents Prepare for Illness and Solutions

Updated Category News Views 191

Back to School: Parents Brace for Sickness A recent survey shows that as children head back to the classroom, many parents anticipate facing a wave of illnesses at home. Conducted by Boiron, a leader in homeopathic remedies, this nationwide survey reveals parents' concerns about the inevitable germs that come along with the school year. Survey Insights on Parental...

Continue Reading
Scarf Systems Achieves SOC 2 Type 2 Examination Success

Updated Category News Views 72

Scarf Systems, Inc. completed a SOC 2 Type 2 examination back in early 2023, solidifying its place as a frontrunner in data security. This wasn't just some routine check; it was a deep dive into how well Scarf protected customer data and adhered to stringent safety protocols. But here’s the kicker—traders started asking: is this enough to keep investors calm? What’s...

Continue Reading